SARS-CoV-2 Spike receptor binding domain, RBD (348-357) – 0.5 mg

Overview

The SARS-CoV-2 Spike receptor binding domain, RBD (348-357) peptide is a crucial sequence for researchers studying the interactions between the spike protein and human cell receptors. This peptide sequence corresponds to residues 348-357 of the receptor binding domain identified from the RefSeq entry YP_009724390.1. Understanding the binding affinity of this peptide is vital for developing therapies and vaccines against COVID-19.

Key Features

• High purity and quality for reliable research outcomes
• Specifically designed for studying SARS-CoV-2 interactions
• Ideal for various applications including ELISA, Western blotting, and immunoassays
• Produced using advanced synthesis techniques to ensure integrity
• Available in a convenient 0.5 mg format

Specifications

FAQ

What is the significance of the RBD in SARS-CoV-2 research?

The receptor binding domain is critical for viral entry into host cells. It’s a key target for vaccine development and therapeutic interventions.

How can I use this peptide in my experiments?

This peptide can be utilized in various assays including ELISA and Western blot for studying protein interactions and binding affinities.

Where can I find more peptide products?

You can explore our extensive selection of peptides, including those like PKG Substrate and Autocamtide-2on our Peptides catalog page.

Order the SARS-CoV-2 Spike receptor binding domain, RBD (348-357) peptide today to enhance your research on viral interactions and therapeutic development.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled

Browse more in Peptides.